PanCAN PurpleStride Chicago welcomes first time Premier Sponsor Endevica Bio, who is dedicated to advancing novel treatments ...
"Cancer-related cachexia and sarcopenia occur in hematologic malignancies, not just gastrointestinal carcinomas and head and neck cancers. Their presence affects all aspects of diagnosis and treatment ...
Kalohexis' lead programs include 710GO, an oral dual melanocortin-3 and-4 receptor (MC3R/MC4R) agonist, a next-generation general obesity treatment; and mifomelatide, a dual MC3R/MC4R antagonist to ...
A majority of people with advanced cancers endure cachexia, a muscle-, fat-, and organ-wasting condition that is currently ...
London, UK – 7 September 2023. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and ...
A new approach using lipid nanoparticles to deliver genetic material is showing promise in tackling two major challenges in ...
Oregon State University researchers have developed engineered lipid nanoparticles that deliver follistatin mRNA directly to lung tumours, simultaneously targeting cancer growth and muscle-wasting ...
Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology’s most ...
This schematic illustration shows the major organs that are affected by and contribute to the development of pancreatic cancer cachexia. With pancreatic cancer at the center of the crosstalk network, ...
Kalohexis' lead programs include 710GO, an oral dual melanocortin-3 and-4 receptor (MC3R/MC4R) agonist, a next-generation general obesity treatment; and mifomelatide, a dual MC3R/MC4R antagonist to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results